Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun;8(6):461-468.
doi: 10.1016/j.jchf.2019.12.013. Epub 2020 May 6.

Outcomes in Patients With Cardiac Amyloidosis Undergoing Heart Transplantation

Christopher D Barrett  1 , Kevin M Alexander  2 , Hongyu Zhao  3 , Francois Haddad  2 , Paul Cheng  2 , Ronglih Liao  2 , Matthew T Wheeler  2 , Michaela Liedtke  2 , Stanley Schrier  2 , Sally Arai  2 , Dana Weisshaar  3 , Ronald M Witteles  4
Affiliations
Free article

Outcomes in Patients With Cardiac Amyloidosis Undergoing Heart Transplantation

Christopher D Barrett et al. JACC Heart Fail. 2020 Jun.
Free article

Abstract

Objectives: The purpose of this study is to report outcomes after heart transplantation in patients with cardiac amyloidosis based on a large single-center experience.

Background: Cardiac amyloidosis causes significant morbidity and mortality, often leading to restrictive cardiomyopathy, progressive heart failure, and death. Historically, heart transplantation outcomes have been worse in patients with cardiac amyloidosis compared with other heart failure populations, in part due to the systemic nature of the disease. However, several case series have suggested that transplantation outcomes may be better in the contemporary era, likely in part due to the availability of more effective light chain suppressive therapies for light chain amyloidosis.

Methods: This study examined all patients seen between 2004 and 2017, either at the Stanford University Medical Center or the Kaiser Permanente Santa Clara Medical Center, who were diagnosed with cardiac amyloidosis and ultimately underwent heart transplantation. This study examined pre-transplantation characteristics and post-transplantation outcomes in this group compared with the overall transplantation population at our center.

Results: During the study period, 31 patients (13 with light chain amyloidosis and 18 with transthyretin [ATTR] amyloidosis) underwent heart transplantation. Patients with ATTR amyloidosis were older, were more likely to be male, had worse baseline renal function, and had longer waitlist times compared with both patients with light chain amyloidosis and the overall transplantation population. Post-transplantation, there were no differences in post-operative bleeding, renal failure, infection, rejection, or malignancy. There was no significant difference in mortality between patients who underwent heart transplantation for amyloid cardiomyopathy and patients who underwent heart transplantation for all other indications.

Conclusions: In carefully selected patients with cardiac amyloidosis, heart transplantation can be an effective therapeutic option with outcomes similar to those transplanted for other causes of heart failure.

Keywords: amyloidosis; cardiac amyloidosis; heart transplantation; infiltrative cardiomyopathy.

PubMed Disclaimer

Comment in

  • Should We Be for ASCT?: If Yes, Then When?
    Trachtenberg BH, Kamble R, Bhimaraj A, Estep JD. Trachtenberg BH, et al. JACC Heart Fail. 2020 Aug;8(8):695-696. doi: 10.1016/j.jchf.2020.05.009. JACC Heart Fail. 2020. PMID: 32731949 No abstract available.
  • Reply: Should We Be for ASCT?: If Yes, Then When?
    Witteles RM, Barrett CD. Witteles RM, et al. JACC Heart Fail. 2020 Aug;8(8):696-697. doi: 10.1016/j.jchf.2020.05.008. JACC Heart Fail. 2020. PMID: 32731950 No abstract available.